Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

969030

registered interest
date	06/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent steps the Government has taken to ensure that (a) negotiations between Vertex Pharmaceuticals and NHS England on access to Orkambi for people with cystic fibrosis proceed without further delay and (b) an agreement is reached between the two parties.
tabling member constituency	Thornbury and Yate
tabling member printed	Luke Hall
uin	171383
answer	answer is ministerial correction date of answer 14/09/2018 answer text <p>It is crucial that patients have access to the most effective and innovative medicines at a price that represents value to the National Health Service. While Ministers are keeping a very close eye on negotiations, it is the responsibility of NHS England as the commissioner and the National Institute for Health and Care Excellence (NICE) as the independent body that is responsible for making recommendations on whether drugs and other treatments represent a clinically and cost-effective use of NHS resources, to work with Vertex to agree a deal to secure the best outcome for patients and a price for Orkambi that is fair and responsible.</p><p> </p><p>NHS England has proposed its best offer ever for a drug. This offer, in the region of £500 million over five years, is the largest ever commitment of its kind in the 70-year history of the NHS. This would guarantee immediate and expanded access to both Orkambi and the drug Kalydeco for patients who need it. Whilst it is disappointing that Vertex has not taken up NHS England’s offer, we are pleased to hear that it has responded positively to NHS England’s and NICE’s latest offer to meet. The Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy), the Secretary of State for Health (Rt. hon. Matt Hancock MP) and I have and continue to urge Vertex to reconsider this fair offer.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 171384 question first answered 14/09/2018 13:32:27 answering member 4067 label Biography information for Steve Brine
tabling member	4450 label Biography information for Luke Hall

969031

registered interest
date	06/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the oral contribution of the Parliamentary Under-Secretary of State for Health and Social Care of 17 July 2018, Official Report, column 384, what progress the Government has made on access to Orkambi in England since Vertex Pharmaceuticals was called on to accept NHS England’s proposal to make that drug available to people with cystic fibrosis.
tabling member constituency	Thornbury and Yate
tabling member printed	Luke Hall
uin	171384
answer	answer is ministerial correction date of answer 14/09/2018 answer text <p>It is crucial that patients have access to the most effective and innovative medicines at a price that represents value to the National Health Service. While Ministers are keeping a very close eye on negotiations, it is the responsibility of NHS England as the commissioner and the National Institute for Health and Care Excellence (NICE) as the independent body that is responsible for making recommendations on whether drugs and other treatments represent a clinically and cost-effective use of NHS resources, to work with Vertex to agree a deal to secure the best outcome for patients and a price for Orkambi that is fair and responsible.</p><p> </p><p>NHS England has proposed its best offer ever for a drug. This offer, in the region of £500 million over five years, is the largest ever commitment of its kind in the 70-year history of the NHS. This would guarantee immediate and expanded access to both Orkambi and the drug Kalydeco for patients who need it. Whilst it is disappointing that Vertex has not taken up NHS England’s offer, we are pleased to hear that it has responded positively to NHS England’s and NICE’s latest offer to meet. The Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy), the Secretary of State for Health (Rt. hon. Matt Hancock MP) and I have and continue to urge Vertex to reconsider this fair offer.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 171383 question first answered 14/09/2018 13:32:27 answering member 4067 label Biography information for Steve Brine
tabling member	4450 label Biography information for Luke Hall

969036

registered interest
date	06/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cervical Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the take-up rate for cervical screening was in (a) the North West and (b) Wallasey constituency in each of the last 10 years.
tabling member constituency	Wallasey
tabling member printed	Ms Angela Eagle
uin	171297
answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>The most recent quarterly data (quarter three) on coverage for women aged 25-49 years and 50- 64 years is from December 2017 and is calculated by clinical commissioning group (CCG) and general practice. This data is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/cervical-screening-coverage-and-data" target="_blank">https://www.gov.uk/government/publications/cervical-screening-coverage-and-data</a></p><p> </p><p>It is reported that Wirral CCG, which covers Wallasey, obtained a coverage rate of 70.43% for women aged 25- 49 years (at a 3.5 year coverage) and 73.19% for women aged 50-64 years (at a 5.5 year coverage).</p><p> </p><p>Coverage data for the North West region is available in the following table.</p><p> </p><p>Data prior to 2015/16 are not available in the format requested.</p><p> </p><p>Age appropriate coverage for women aged 25-64 years</p><table><tbody><tr><td colspan="3"><p>England regions, 31 March 2016 and 2017 percentages age appropriate coverage</p></td></tr><tr><td colspan="3"><p>(Less than 3.5 / 5.5 years since last adequate test)</p></td></tr><tr><td><p>Region</p></td><td><p>2016</p></td><td><p>2017</p></td></tr><tr><td><p>North East</p></td><td><p>75.2</p></td><td><p>74.7</p></td></tr><tr><td><p>Yorkshire and the Humber</p></td><td><p>75.4</p></td><td><p>74.9</p></td></tr><tr><td><p>North West</p></td><td><p>72.3</p></td><td><p>72.0</p></td></tr><tr><td><p>East Midlands</p></td><td><p>75.9</p></td><td><p>75.4</p></td></tr><tr><td><p>West Midlands</p></td><td><p>71.8</p></td><td><p>71.4</p></td></tr><tr><td><p>East of England</p></td><td><p>73.9</p></td><td><p>73.3</p></td></tr><tr><td><p>London</p></td><td><p>66.7</p></td><td><p>65.7</p></td></tr><tr><td><p>South East</p></td><td><p>74.3</p></td><td><p>73.5</p></td></tr><tr><td><p>South West</p></td><td><p>74.8</p></td><td><p>74.1</p></td></tr></tbody></table><p> </p><p>Source: NHS Digital: <a href="https://files.digital.nhs.uk/pdf/t/b/cervical_bulletin_report_2016-17_-_final.pdf" target="_blank">https://files.digital.nhs.uk/pdf/t/b/cervical_bulletin_report_2016-17_-_final.pdf</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/09/2018 15:10:36 answering member 4067 label Biography information for Steve Brine
tabling member	491 label Biography information for Dame Angela Eagle

969055

registered interest
date	06/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	WHO Framework Convention on Tobacco Control
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, who will be representing the UK at the eighth Conference of the Parties to the World Health Organisation Framework Convention on tobacco control in October 2018.
tabling member constituency	Kettering
tabling member printed	Mr Philip Hollobone
uin	171320
answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>The United Kingdom Government will be represented at the eighth Conference of the Parties (CoP) to the World Health Organization Framework Convention on tobacco control (FCTC) by three officials from the Department and the UK Permanent Representation to the European Union. The delegation will be led by Tim Baxter, Deputy Director of Healthy Behaviours at the Department.</p><p>A figure for the costs associated with attendance at the CoP is not yet available. Every effort has been made to keep costs to a minimum to ensure value for money.</p><p>As a world leader in tobacco control the UK has been, and will continue to be, a highly active participant in the FCTC. The UK will participate in the CoP as a member state of the European Union. The UK will continue to support measures to reduce global harms from tobacco, building on its strong domestic record in reducing smoking, and will work to ensure that the work of the FCTC secretariat is both effective and provides value for money.</p><p> </p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 171321 171322 question first answered 11/09/2018 14:43:02 answering member 4067 label Biography information for Steve Brine
tabling member	1537 label Biography information for Mr Philip Hollobone

969056

registered interest
date	06/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	WHO Framework Convention on Tobacco Control
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost to the public purse of the UK's representation at the eighth conference of the parties to the World Health Organisation framework convention on tobacco control in October 2018.
tabling member constituency	Kettering
tabling member printed	Mr Philip Hollobone
uin	171321
answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>The United Kingdom Government will be represented at the eighth Conference of the Parties (CoP) to the World Health Organization Framework Convention on tobacco control (FCTC) by three officials from the Department and the UK Permanent Representation to the European Union. The delegation will be led by Tim Baxter, Deputy Director of Healthy Behaviours at the Department.</p><p>A figure for the costs associated with attendance at the CoP is not yet available. Every effort has been made to keep costs to a minimum to ensure value for money.</p><p>As a world leader in tobacco control the UK has been, and will continue to be, a highly active participant in the FCTC. The UK will participate in the CoP as a member state of the European Union. The UK will continue to support measures to reduce global harms from tobacco, building on its strong domestic record in reducing smoking, and will work to ensure that the work of the FCTC secretariat is both effective and provides value for money.</p><p> </p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 171320 171322 question first answered 11/09/2018 14:43:02 answering member 4067 label Biography information for Steve Brine
tabling member	1537 label Biography information for Mr Philip Hollobone

969058

registered interest
date	06/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	WHO Framework Convention on Tobacco Control
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the strategic objectives of his departmental delegation will be at the eighth conference of the parties to the World Health Organisation framework convention on tobacco control in October 2018.
tabling member constituency	Kettering
tabling member printed	Mr Philip Hollobone
uin	171322
answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>The United Kingdom Government will be represented at the eighth Conference of the Parties (CoP) to the World Health Organization Framework Convention on tobacco control (FCTC) by three officials from the Department and the UK Permanent Representation to the European Union. The delegation will be led by Tim Baxter, Deputy Director of Healthy Behaviours at the Department.</p><p>A figure for the costs associated with attendance at the CoP is not yet available. Every effort has been made to keep costs to a minimum to ensure value for money.</p><p>As a world leader in tobacco control the UK has been, and will continue to be, a highly active participant in the FCTC. The UK will participate in the CoP as a member state of the European Union. The UK will continue to support measures to reduce global harms from tobacco, building on its strong domestic record in reducing smoking, and will work to ensure that the work of the FCTC secretariat is both effective and provides value for money.</p><p> </p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 171320 171321 question first answered 11/09/2018 14:43:02 answering member 4067 label Biography information for Steve Brine
tabling member	1537 label Biography information for Mr Philip Hollobone

969062

registered interest
date	06/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tobacco
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress his Department has made in tendering for the grant scheme relating to external stakeholder support for the tobacco control plan.
tabling member constituency	Kettering
tabling member printed	Mr Philip Hollobone
uin	171323
answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>The grant scheme to secure additional support to assist in the delivery of commitments made in the tobacco control plan was advertised in May and June 2018. Ten eligible organisations applied for this funding.</p><p>The Department reviewed these applications as per Cabinet Office guidelines in July and finalised this in August. Action on Smoking and Health (ASH) in a partnership application with FRESH North East scored the highest. All applicants have been informed of the results and paperwork is currently being finalised in order to award the grant to ASH and FRESH North East.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/09/2018 14:29:34 answering member 4067 label Biography information for Steve Brine
tabling member	1537 label Biography information for Mr Philip Hollobone

969083

registered interest
date	06/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of levels of funding on the ability of the NHS to increase access to radiotherapy.
tabling member constituency	Easington
tabling member printed	Grahame Morris
uin	171339
answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>Since 2016, the Radiotherapy Modernisation programme has seen £130 million of new funding invested in improving radiotherapy equipment. As a result, the National Health Service has so far received 73 new or upgraded linear accelerators, enabling the delivery of advanced treatment techniques and faster treatment times. From April 2019, NHS England will be establishing 11 Radiotherapy Networks to build on this investment and lead the development of services at a local level. This will include ensuring that every patient benefits from best clinical practice and has access to innovative and advanced treatments and techniques.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/09/2018 15:02:53 answering member 4067 label Biography information for Steve Brine
tabling member	3973 label Biography information for Grahame Morris

969086

registered interest
date	06/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how NHS England monitors clinical commissionng groups' cancer treatment performance in respect of access to advanced radiotherapy; and what steps NHS England takes to address instances of poor performance.
tabling member constituency	Easington
tabling member printed	Grahame Morris
uin	171340
answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>Clinical commissioning groups are not responsible for ensuring access to advanced radiotherapy techniques, such as Intensity Modulated Radiotherapy (IMRT). The commissioning of all radiotherapy in England is the responsibility of NHS England’s Specialised Commissioning team. Access to IMRT is monitored against a national average access standard of 25%, performance against this standard is consistently around 45%. From April 2019, Radiotherapy Networks, working in close partnership with Specialised Commissioners and Cancer Alliances, will play a key role in increasing access to both advanced and innovative radiotherapy, as well as ensuring adherence to best practice treatment protocols.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 170800 question first answered 11/09/2018 14:23:08 answering member 4067 label Biography information for Steve Brine
tabling member	3973 label Biography information for Grahame Morris

969106

registered interest
date	06/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescriptions: Delivery Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the annual cost to the NHS is of providing a prescription delivery service.
tabling member constituency	Easington
tabling member printed	Grahame Morris
uin	171350
answer	answer is ministerial correction date of answer 13/09/2018 answer text <p>We have made no assessment of the cost of such a service. The home delivery of prescription medicines are provided at a contractor’s discretion or can be commissioned locally by the National Health Service.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 13/09/2018 16:22:06 answering member 4067 label Biography information for Steve Brine
tabling member	3973 label Biography information for Grahame Morris